Stomach/Duodenum News

The CDC expanded its warning on eating charcuterie meats after the number of cases in a multistate Salmonella outbreak doubled over the last 2 weeks.

Perceived stress and certain gastrointestinal factors were linked to menopausal symptoms, with reproductive stages, physical activity, BMI and previously diagnosed depression or anxiety affecting symptom severity, researchers reported.

Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

VANCOUVER, British Columbia — As-needed vagal nerve stimulation reduced rescue mediation use among patients with nausea related to gastroparesis or functional dyspepsia, according to data presented at the ACG Annual Scientific Meeting.

The FDA has granted conditional use with magnetic resonance imaging to Enterra Medical’s implantable electrical stimulation device for management of symptoms associated with gastroparesis, according to a company release.

VANCOUVER, British Columbia — Tirzepatide 15 mg was associated with the highest degree of weight loss compared with other glucagon-like peptide-1 agonists and placebo, according to a presenter at the ACG Annual Scientific Meeting.

Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.

Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.

More than half of patients treated with antibiotics for acute appendicitis avoided surgery for up to 25 years, with researchers reporting no evidence of long-term risks with nonoperative management other than recurrence.